Explore the Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Castration-Resistant Prostate Cancer (CRPC) Treatment Market

Key Insight

Castration-resistant prostate cancer (CRPC) treatment sales will strengthen through 2036, anchored by hormonal therapy at 42.6% of the therapy type in 2026. The market was valued at USD 13.53 billion in 2025 and is expected to be worth USD 36.63 billion by 2036, creating an incremental opportunity of USD 21.85 billion.

May 26, 2026

Anurag Sharma

293 Pages

Cite this Report

Castration-Resistant Prostate Cancer (CRPC) Treatment Market

https://www.futuremarketinsights.com/reports/castration-resistant-prostate-cancer-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Abbott Laboratories
Amgen
BlackRock
Bayer
Bristol-Myers Squibb
Clovis Oncology
Dendreon Corporation
Endo Pharmaceuticals Inc
GSK
The Vanguard Group
Merck KGaA
Novartis
Pfizer Inc. / Astellas Pharma
L'Oréal

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Castration-Resistant Prostate Cancer (CRPC) Treatment Market

Key Players

Similar Industry Reports